Communication to Shareholders, page-229

maybe not the 1st brickie

from the 18th may 2022 announcement

"To establish the new use claims, AnteoTech completed analytical and clinical performance evaluations in the US and the UK respectively, that focussed on validating the test’s effectiveness in detecting the Omicron variant of SARS-CoV-2, the dominant variant currently circulating globally. This work will be used in future regulatory submissions."

so we have "completed analytical and clinical performance evaluations in the US" just one of Anteotech's advancements I hope to hear about in the upcoming quarterly.